Role of Transient Receptor Potential Vanilloid 1 in Inflammation and Autoimmune Diseases
Transient receptor potential vanilloid 1 (TRPV1), a non-selective cation channel, is a receptor activated by high temperatures and chemical agonists such as the vanilloids and protons. Because of these properties, TRPV1 has emerged as a polymodal nocisensor of nociceptive afferent neurons. TRPV1 is...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2012-08-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | http://www.mdpi.com/1424-8247/5/8/837 |
| _version_ | 1811206468589846528 |
|---|---|
| author | Fumio Tsuji Hiroyuki Aono |
| author_facet | Fumio Tsuji Hiroyuki Aono |
| author_sort | Fumio Tsuji |
| collection | DOAJ |
| description | Transient receptor potential vanilloid 1 (TRPV1), a non-selective cation channel, is a receptor activated by high temperatures and chemical agonists such as the vanilloids and protons. Because of these properties, TRPV1 has emerged as a polymodal nocisensor of nociceptive afferent neurons. TRPV1 is thought to be a central transducer of hyperalgesia and a prime target for controlling pain pharmacologically because it is a point where many proalgesic pathways converge and it is upregulated and sensitized by inflammation and injury. However, whether TRPV1 agonists promote or inhibit inflammation remains unclear. We recently demonstrated that SA13353 (1-[2-(1-adamantyl)ethyl]-1-pentyl-3-[3-(4-pyridyl)propyl]urea), a novel TRPV1 agonist, inhibits tumor necrosis factor-a production by the activation of capsaicin-sensitive afferent neurons and reduces the severity of symptoms in kidney injury, lung inflammation, arthritis, and encephalomyelitis. These results suggest that TRPV1 agonists may act as anti-inflammatories in certain inflammatory and autoimmune conditions <em>in vivo</em>. Given the potential deleterious effects of inhibiting the population of channels with a protective function, caution should be taken in the use of potent TRPV1 antagonists as a general strategy to treat inflammation. Further studies are required to clarify the role of TRPV1 and neuropeptides, which are released because of TRPV1 activation in inflammation and autoimmune diseases. |
| first_indexed | 2024-04-12T03:49:08Z |
| format | Article |
| id | doaj.art-eaca8978d59f40c3a488447427ca9e09 |
| institution | Directory Open Access Journal |
| issn | 1424-8247 |
| language | English |
| last_indexed | 2024-04-12T03:49:08Z |
| publishDate | 2012-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceuticals |
| spelling | doaj.art-eaca8978d59f40c3a488447427ca9e092022-12-22T03:49:03ZengMDPI AGPharmaceuticals1424-82472012-08-015883785210.3390/ph5080837Role of Transient Receptor Potential Vanilloid 1 in Inflammation and Autoimmune DiseasesFumio TsujiHiroyuki AonoTransient receptor potential vanilloid 1 (TRPV1), a non-selective cation channel, is a receptor activated by high temperatures and chemical agonists such as the vanilloids and protons. Because of these properties, TRPV1 has emerged as a polymodal nocisensor of nociceptive afferent neurons. TRPV1 is thought to be a central transducer of hyperalgesia and a prime target for controlling pain pharmacologically because it is a point where many proalgesic pathways converge and it is upregulated and sensitized by inflammation and injury. However, whether TRPV1 agonists promote or inhibit inflammation remains unclear. We recently demonstrated that SA13353 (1-[2-(1-adamantyl)ethyl]-1-pentyl-3-[3-(4-pyridyl)propyl]urea), a novel TRPV1 agonist, inhibits tumor necrosis factor-a production by the activation of capsaicin-sensitive afferent neurons and reduces the severity of symptoms in kidney injury, lung inflammation, arthritis, and encephalomyelitis. These results suggest that TRPV1 agonists may act as anti-inflammatories in certain inflammatory and autoimmune conditions <em>in vivo</em>. Given the potential deleterious effects of inhibiting the population of channels with a protective function, caution should be taken in the use of potent TRPV1 antagonists as a general strategy to treat inflammation. Further studies are required to clarify the role of TRPV1 and neuropeptides, which are released because of TRPV1 activation in inflammation and autoimmune diseases.http://www.mdpi.com/1424-8247/5/8/837SA13353transient receptor potential vanilloid 1kidney injurylung inflammationautoimmune diseasespain |
| spellingShingle | Fumio Tsuji Hiroyuki Aono Role of Transient Receptor Potential Vanilloid 1 in Inflammation and Autoimmune Diseases Pharmaceuticals SA13353 transient receptor potential vanilloid 1 kidney injury lung inflammation autoimmune diseases pain |
| title | Role of Transient Receptor Potential Vanilloid 1 in Inflammation and Autoimmune Diseases |
| title_full | Role of Transient Receptor Potential Vanilloid 1 in Inflammation and Autoimmune Diseases |
| title_fullStr | Role of Transient Receptor Potential Vanilloid 1 in Inflammation and Autoimmune Diseases |
| title_full_unstemmed | Role of Transient Receptor Potential Vanilloid 1 in Inflammation and Autoimmune Diseases |
| title_short | Role of Transient Receptor Potential Vanilloid 1 in Inflammation and Autoimmune Diseases |
| title_sort | role of transient receptor potential vanilloid 1 in inflammation and autoimmune diseases |
| topic | SA13353 transient receptor potential vanilloid 1 kidney injury lung inflammation autoimmune diseases pain |
| url | http://www.mdpi.com/1424-8247/5/8/837 |
| work_keys_str_mv | AT fumiotsuji roleoftransientreceptorpotentialvanilloid1ininflammationandautoimmunediseases AT hiroyukiaono roleoftransientreceptorpotentialvanilloid1ininflammationandautoimmunediseases |